-
2026-06-05 00:20
-
2026-06-04 21:33
-
2026-06-04 19:58
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a who
-
2026-06-04 19:56
-
2026-06-04 19:00
-
2026-06-04 18:09
-
2026-06-04 17:39
-
2026-06-04 16:22
-
2026-06-04 09:09
BROOMFIELD, Colo., June 4, 2026 /PRNewswire/ -- Quantinuum Inc. ("Quantinuum") today announced the pricing of the upsized initial public offering of 28,000,000 sharesof its Class A common stock at a price to the public of $60.00 per share. Quantinuum has granted the underwriters
-
2026-06-04 09:00